NCT03607539View on ClinicalTrials.gov

Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC

PHASE3CompletedINTERVENTIONAL
Enrollment

397

Participants

Timeline

Start Date

August 23, 2018

Primary Completion Date

February 13, 2023

Study Completion Date

February 13, 2023

Conditions
Lung Neoplasms
Interventions
DRUG

Sintilimab

10 mL:100 mg，200mg，Q3W (qualer 3 weeks), day1, I.V.

DRUG

Pemetrexed

500mg/m\^2; Q3W (qualer 3 weeks), day1, I.V.

DRUG

Platinum

Q3W (qualer 3 weeks), day1, I.V.; first 4 cycles.

DRUG

Placebos

10 mL:100 mg，200mg，Q3W (qualer 3 weeks), day1, I.V.

Trial Locations (1)

Unknown

Sun Yat-Sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT03607539 - Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC | Biotech Hunter | Biotech Hunter